• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Successful allogeneic CD34 hematopoietic stem cell boost for prolonged cytopenias following CAR T-cell therapy in B-cell acute lymphoblastic leukemia. On behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC).

作者信息

Molinos-Quintana Águeda, Martínez-Cibrian Nuria, Alonso-Saladrigues Anna, Galán-Gómez Víctor, Bailén Rebeca, Buendía-López Susana, Fuentes-Socorro Carolina, Kwon Mi, González-Vincent Marta, Pérez de Soto Concepción, González-Martínez Berta, Rives Susana, Pérez-Hurtado José María, Ortiz-Maldonado Valentín, Pérez-Simón José Antonio

机构信息

Pediatric Unit, Department of Hematology, University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS) / CSIC, Universidad de Sevilla, Seville, Spain.

Haematology Department, Hospital Clinic de Barcelona, Barcelona, Spain.

出版信息

Bone Marrow Transplant. 2025 Feb;60(2):250-253. doi: 10.1038/s41409-024-02473-2. Epub 2024 Nov 17.

DOI:10.1038/s41409-024-02473-2
PMID:39551836
Abstract
摘要

相似文献

1
Successful allogeneic CD34 hematopoietic stem cell boost for prolonged cytopenias following CAR T-cell therapy in B-cell acute lymphoblastic leukemia. On behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC).成功进行异基因CD34造血干细胞增强治疗，用于治疗B细胞急性淋巴细胞白血病患者接受CAR T细胞治疗后出现的长期血细胞减少症。西班牙造血移植与细胞治疗小组（GETH-TC）代表发言。
Bone Marrow Transplant. 2025 Feb;60(2):250-253. doi: 10.1038/s41409-024-02473-2. Epub 2024 Nov 17.
2
Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell Therapy.BCMA 靶向 CAR T 细胞治疗后造血恢复延迟时使用 CD34+ 干细胞增强的疗效和安全性。
Transplant Cell Ther. 2023 Sep;29(9):567-571. doi: 10.1016/j.jtct.2023.05.012. Epub 2023 May 22.
3
Post-transplant relapse in pediatric acute lymphoblastic leukemia in the era of CAR-T cell therapy. A multicenter analysis of Grupo Español de Trasplante Hematopoyetico y Terapia Celular (GETH-TC) Pediatric Committee.嵌合抗原受体T细胞（CAR-T）疗法时代小儿急性淋巴细胞白血病的移植后复发。西班牙血液移植与细胞治疗协作组（GETH-TC）儿科委员会的多中心分析
Cytotherapy. 2025 Apr;27(4):438-445. doi: 10.1016/j.jcyt.2024.11.016. Epub 2024 Dec 2.
4
Allogeneic CD34-selected stem cell boost as salvage treatment of life-threatening infection and severe cytopenias after CAR-T cell therapy.异基因 CD34 选择的干细胞增强作为 CAR-T 细胞治疗后危及生命的感染和严重细胞减少症的挽救治疗。
Transfusion. 2022 Oct;62(10):2143-2147. doi: 10.1111/trf.17071. Epub 2022 Aug 20.
5
Case Report: Successful engraftment of allogeneic hematopoietic stem cells using CAR-T cell therapy as the conditioning regimen in R/R Ph B cell acute lymphoblastic leukemia.病例报告：在复发/难治性费城染色体阳性 B 细胞急性淋巴细胞白血病中，使用 CAR-T 细胞治疗作为预处理方案，成功进行异基因造血干细胞移植。
Front Immunol. 2022 Sep 26;13:965932. doi: 10.3389/fimmu.2022.965932. eCollection 2022.
6
Allogeneic CD34 selected hematopoietic stem cell boost following CAR T-cell therapy in a patient with prolonged cytopenia and active infection.患者因血细胞减少症持续存在和活动性感染而接受 CAR T 细胞治疗后，进行同种异体 CD34 选择造血干细胞增强。
Pediatr Blood Cancer. 2023 Mar;70(3):e30166. doi: 10.1002/pbc.30166. Epub 2022 Dec 24.
7
Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia.嵌合抗原受体 T 细胞疗法与移植的整合：CAR T 细胞或基于化疗的完全缓解后异基因造血干细胞移植在 B 细胞急性淋巴细胞白血病中的安全性和长期疗效比较。
Front Immunol. 2021 May 7;12:605766. doi: 10.3389/fimmu.2021.605766. eCollection 2021.
8
Donor-Derived CD7 CAR-T Therapy Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Acute T-Lymphocytic Leukemia Associated With Hepatitis B: A Case Report.供体来源 CD7 CAR-T 治疗联合异基因造血干细胞移植治疗乙型肝炎相关急性 T 淋巴细胞白血病：一例报告。
Front Immunol. 2022 Jul 12;13:931452. doi: 10.3389/fimmu.2022.931452. eCollection 2022.
9
[Maintenance therapy following CD19 CAR-T treatment for relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].异基因造血干细胞移植后复发的B细胞急性淋巴细胞白血病经CD19嵌合抗原受体T细胞（CAR-T）治疗后的维持治疗
Zhonghua Xue Ye Xue Za Zhi. 2020 Jun 14;41(6):495-501. doi: 10.3760/cma.j.issn.0253-2727.2020.06.011.
10
Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation.CD19嵌合抗原受体T细胞疗法治疗异基因造血干细胞移植后复发的急性淋巴细胞白血病患者的疗效与安全性。
Int J Hematol. 2022 Sep;116(3):315-329. doi: 10.1007/s12185-022-03398-6. Epub 2022 Jun 23.

本文引用的文献

1
A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy.嵌合抗原受体 T 细胞治疗后非复发死亡率的系统评价和荟萃分析。
Nat Med. 2024 Sep;30(9):2667-2678. doi: 10.1038/s41591-024-03084-6. Epub 2024 Jul 8.
2
Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations.免疫效应细胞相关血液学毒性：EHA/EBMT 共识分级和最佳实践建议。
Blood. 2023 Sep 7;142(10):865-877. doi: 10.1182/blood.2023020578.
3
An International Survey on Grading, Diagnosis, and Management of Immune Effector Cell-Associated Hematotoxicity (ICAHT) Following CAR T-cell Therapy on Behalf of the EBMT and EHA.
代表欧洲血液与骨髓移植协会（EBMT）和欧洲血液学协会（EHA）开展的关于嵌合抗原受体（CAR）T细胞治疗后免疫效应细胞相关血液毒性（ICAHT）分级、诊断和管理的国际调查。
Hemasphere. 2023 Apr 27;7(5):e889. doi: 10.1097/HS9.0000000000000889. eCollection 2023 May.
4
Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party.CD19 CAR T 细胞治疗后严重细胞减少症：来自 EBMT 移植并发症工作组的回顾性研究。
J Immunother Cancer. 2023 Apr;11(4). doi: 10.1136/jitc-2022-006406.
5
How I treat cytopenias after CAR T-cell therapy.我如何治疗 CAR T 细胞治疗后的血细胞减少症。
Blood. 2023 May 18;141(20):2460-2469. doi: 10.1182/blood.2022017415.
6
Allogeneic CD34 selected hematopoietic stem cell boost following CAR T-cell therapy in a patient with prolonged cytopenia and active infection.患者因血细胞减少症持续存在和活动性感染而接受 CAR T 细胞治疗后，进行同种异体 CD34 选择造血干细胞增强。
Pediatr Blood Cancer. 2023 Mar;70(3):e30166. doi: 10.1002/pbc.30166. Epub 2022 Dec 24.
7
Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy.干细胞增强疗法作为CD19嵌合抗原受体T细胞疗法后严重血液毒性挽救治疗的安全性和可行性。
Blood Adv. 2022 Aug 23;6(16):4719-4725. doi: 10.1182/bloodadvances.2022007776.
8
CD34+-selected stem cell boost can safely improve cytopenias following CAR T-cell therapy.选择CD34+干细胞增强疗法可安全改善CAR T细胞治疗后的血细胞减少症。
Blood Adv. 2022 Aug 23;6(16):4715-4718. doi: 10.1182/bloodadvances.2022007572.
9
Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: a GLA/DRST study.嵌合抗原受体 T 细胞（CAR-T）治疗后持续性中性粒细胞减少症的造血干细胞增强：GLA/DRST 研究。
Blood Adv. 2023 Feb 28;7(4):555-559. doi: 10.1182/bloodadvances.2022008042.
10
GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany.德国 GLA/DRST 真实世界研究分析嵌合抗原受体 T 细胞疗法治疗大 B 细胞淋巴瘤的结果。
Blood. 2022 Jul 28;140(4):349-358. doi: 10.1182/blood.2021015209.